Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $3.30 price target on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Price Performance

AWH opened at $2.98 on Thursday. The firm has a fifty day moving average price of $3.38 and a 200 day moving average price of $3.87. Aspira Women’s Health has a 1 year low of $2.31 and a 1 year high of $6.75. The stock has a market cap of $36.77 million, a P/E ratio of -0.25 and a beta of 1.57.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.09. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 176.74%. The company had revenue of $2.13 million for the quarter, compared to the consensus estimate of $2.70 million. Equities analysts expect that Aspira Women’s Health will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

Several hedge funds have recently bought and sold shares of AWH. Quantum Private Wealth LLC grew its stake in shares of Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after acquiring an additional 21,788 shares in the last quarter. Northeast Financial Consultants Inc acquired a new position in Aspira Women’s Health during the 3rd quarter worth $126,000. B. Riley Wealth Advisors Inc. increased its holdings in Aspira Women’s Health by 39.0% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after purchasing an additional 35,177 shares during the period. Finally, Perkins Capital Management Inc. acquired a new stake in Aspira Women’s Health in the 3rd quarter valued at about $268,000. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.